Trading Markets

Sign Up For Our FREE Newsletter

Searching For The Holy Grail In The Fight Against HIV/AIDS

Today at noon Eastern Time, Feb. 11, VaxGen will hold a conference call discussing its earnings report for the quarter and year ended Dec, 31, 2002. The question on every traderGÇÖs mind is not whether the company made money last month or whether it will make money this year. The big question is w

The Edge In Trading Biotech

The unique aspect of biotech that distinguishes trading in this sector from all others is the fact that these companies tell you when their big move will occur. Yes, they make it known willingly and translate this information in many ways. Where else can you research a company and accurately know in advance w

Seven Stocks To Watch

The next six months are going to be very nerve racking for Genentech executives as the await the release of several key decisions and medical data. The first key decision does not involve Genentech directly. Biogen (BGEN) anxiously awaits the full FDAGÇÖs decision on its new drug (Amevive) to treat Psoriasis.

FDA Decisions Will Affect These Three Stocks

The FDAGÇÖs Endocrinologic and Metabolic Drug
Advisory Committee met Monday to decide whether GenzymeGÇÖs new
drug to treat the potential fatal inherited Fabry disease had
the potential to be

I’m Excited About Biotech…Here’s Why

I believe there will be significant opportunities for investors to take advantage of in the biotech sector. Investing in biotechnology
companies is never boring and the upcoming year will be no
exception. This year will bring many opportunities for
investors to take advantage of the volatility so inherent in
this industryGÇÖs companies.

FDA Alert: Three Drug Stocks To Watch

The Endocrinologic and Metabolic Drugs Advisory Committee of the FDA will meet from Jan. 13 – 15 to decide the fate of three new Biologics License Applications that will have deep implications on the short-term financial outlook of three companies.-áOn Monday, Jan. 13, the Advisory Committee will first decide whether to approve

FDA Alert: Matrix, IDEC Pharmaceuticals And More…

If you have any comments, questions, or thoughts on this
article or on anything to do on biotechnology or medical
technology, feel free to email me at
prugg@tradingmarkets.com. On Sept. 11 and 12, the FDA
Oncologic Drugs Advisory Committee will meet to decide the
fate of two drugs aimed at treating two different cancers.
Matrix Pharmaceuticals (MATX), a small non-profitable biotech
company, will get its first chance to convince the FDA that
its lead drug, IntraDose, is effective for treating recurrent
head and neck cancer. The drugGÇÖs main ingredient is a known
chemotherapeutic agent that is effective in treating this
disease. Matrix Pharmaceuticals has developed a unique way to
deliver this agent by injecting it directly into the
recurrent head and neck cancer.

FDA Alert: Amgen (AMGN)

On
Thursday, August 16, the FDA Advisory Committee on Arthritis Drugs
will discuss the efficacy and safety of AmgenGÇÖs [AMGN|AMGN] new drug, Kineret

Trading The FDA, Part I

The road to getting a new drug approved offers several stops along the way. In Part 1 of this lesson, I show you where these stops are and the opportunities they present for investors to take advantage of potential movement in the biotech sector.

Trading The FDA, Part II

Once the news is out, enthusiasm for FDA New Drug Applications can be short-lived as investors lose interest. Part II explores choppy patterns as opportunities to plan early entry and exit points, focusing on the biggest prize of all, the FDA approval meeting date.